Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastati...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2014
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4085472/
https://ncbi.nlm.nih.gov/pubmed/24699910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-2923-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky